🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,257 results for “First” Clear

  1. SBRT combined with Nimotuzumab followed by Tislelizumab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial

  2. SBRT combined with PD-1 inhibitors and thoracic hyperthermia

    The First People's Hospital of Lianyungang

    Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC

    phase 2 other active

    1 trial

  3. SHR-1139 Injection

    The First People's Hospital of Lianyungang

    Pyoderma Gangrenosum

    phase 2 small molecule active

    1 trial

  4. SHR-1210

    The First People's Hospital of Lianyungang

    Resectable Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  5. SHR-1701

    The First People's Hospital of Lianyungang

    Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  6. SHR2554/AZA + Overlapped TBF

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 other active

    1 trial

  7. SSGJ-706

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial

  8. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial

  9. Sacituzumab Tirumotecan in combination with tislelizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  10. Sandwich stratergy

    The First People's Hospital of Lianyungang

    Acute Lymphobkastic Leukemia

    phase 2 other active

    1 trial

  11. Savolitinib

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Selinexor

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule active

    1 trial

  13. Semaglutide (Rybelsus®)

    The First People's Hospital of Lianyungang

    Obesity-related Male Infertility

    phase 2 small molecule active

    1 trial

  14. Serplulimab

    The First People's Hospital of Lianyungang

    HER2-positive Gastric Cancer

    phase 2 small molecule active

    1 trial

  15. Serplulimab

    The First People's Hospital of Lianyungang

    Colorectal Cancer (Diagnosis)

    phase 2 small molecule active

    1 trial

  16. Serplulimab

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  17. Serratus Plane block (single injection)

    The First People's Hospital of Lianyungang

    Serratus Plane Block

    phase 2 other active

    1 trial

  18. Sertraline combined with Lactobacillus crispatus

    The First People's Hospital of Lianyungang

    Major Depressive Disorder (MDD)

    phase 2 other active

    1 trial

  19. Sintilimab

    The First People's Hospital of Lianyungang

    Carcinoma

    phase 2 mab active

    1 trial

  20. Sintilimab

    The First People's Hospital of Lianyungang

    Ovarian Clear Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  21. Sintilimab

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule active

    1 trial

  22. Sintilimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  23. Sintilimab

    The First People's Hospital of Lianyungang

    Multiple Primary Lung Cancer

    phase 2 small molecule active

    1 trial

  24. Sintilimab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources